Table 7.
Univariate analysis affecting treatment efficacy
| Effective Group (n=109) | Ineffective Group (n=12) | χ2/t | P | |
|---|---|---|---|---|
| Age (year) | 0.028 | 0.867 | ||
| ≤56 | 39 (35.78) | 4 (33.33) | ||
| >56 | 70 (64.22) | 8 (66.67) | ||
| Age (year) | 57.54±7.66 | 56.83±8.90 | 0.299 | 0.765 |
| Duration of menopause (months) | 4.86±2.27 | 5.00±2.80 | 0.195 | 0.846 |
| BMI (kg/m2) | 1.269 | 0.260 | ||
| ≤23 | 55 (50.46) | 4 (33.33) | ||
| >23 | 54 (49.54) | 8 (66.67) | ||
| BMI (Kg/m2) | 0.072 | 0.943 | ||
| Smoking History | 0.007 | 0.931 | ||
| Yes | 35 (32.11) | 4 (33.33) | ||
| No | 74 (67.89) | 8 (66.67) | ||
| Diabetes | 0.698 | 0.403 | ||
| Yes | 41 (37.61) | 6 (50.00) | ||
| No | 68 (62.39) | 6 (50.00) | ||
| Hypertension | 2.579 | 0.110 | ||
| Yes | 38 (34.86) | 7 (58.33) | ||
| No | 71 (65.14) | 5 (41.67) | ||
| Menopause Years | 1.939 | 0.164 | ||
| ≤4 | 41 (37.61) | 7 (58.33) | ||
| >4 | 68 (62.39) | 5 (41.67) | ||
| Index level before treatment | ||||
| VAS | 7.41±0.86 | 7.17±0.83 | 0.941 | 0.349 |
| Joint function | 46.35±2.46 | 45.58±2.47 | 1.022 | 0.309 |
| Vertebrae bone mineral density (g/cm2) | 0.71±0.08 | 0.68±0.05 | 1.612 | 0.110 |
| Hip bone mineral density (g/cm2) | 0.64±0.06 | 0.66±0.08 | 0.938 | 0.350 |
| Osteocalcin (ng/ml) | 23.48±2.63 | 23.41±1.60 | 0.096 | 0.924 |
| CTX (ng/ml) | 0.50±0.07 | 0.51±0.08 | 0.527 | 0.599 |
| BALP (µg/L) | 19.10±1.37 | 19.39±2.16 | 0.665 | 0.507 |
| Treatment approach | 6.373 | 0.012 | ||
| Tibolone | 49 | 10 | ||
| Tibolone + zoledronic acid | 60 | 2 |
Note: VAS, Visual Analogue Scale; BMI, body mass index; CTX, C-terminal telopeptide of type I collagen; BALP, bone alkaline phosphatase.